Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin + R-CHOP vs R-CHOP in high-risk DLBCL with DGM1 biomarker
CTR20171560Phase 3Completed
- Sponsor
- Denovo Biopharma
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzastaurin in diffuse large B-cell lymphoma (DLBCL), sponsored by Denovo Biopharma. Started Mar 2018; status: completed.
02
Drugs
enzastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20171560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171560.